Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28790340)

  • 1. Verteporfin inhibits growth of human glioma in vitro without light activation.
    Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
    J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
    Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
    Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
    Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
    J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
    Wei C; Li X
    Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
    Dong L; Lin F; Wu W; Liu Y; Huang W
    Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells.
    Xia Y; Zhang YL; Yu C; Chang T; Fan HY
    PLoS One; 2014; 9(11):e109575. PubMed ID: 25369529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
    Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
    ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
    Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
    Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    Wei C; Li X
    BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
    Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
    Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP.
    Kimura TE; Duggirala A; Smith MC; White S; Sala-Newby GB; Newby AC; Bond M
    J Mol Cell Cardiol; 2016 Jan; 90():1-10. PubMed ID: 26625714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway.
    Li M; Lu J; Zhang F; Li H; Zhang B; Wu X; Tan Z; Zhang L; Gao G; Mu J; Shu Y; Bao R; Ding Q; Wu W; Dong P; Gu J; Liu Y
    Cancer Lett; 2014 Dec; 355(2):201-9. PubMed ID: 25218593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
    Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
    Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active epithelial Hippo signaling in idiopathic pulmonary fibrosis.
    Gokey JJ; Sridharan A; Xu Y; Green J; Carraro G; Stripp BR; Perl AT; Whitsett JA
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP knockdown inhibits proliferation and induces apoptosis of human prostate cancer DU145 cells.
    Jin X; Zhao W; Zhou P; Niu T
    Mol Med Rep; 2018 Mar; 17(3):3783-3788. PubMed ID: 29286134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAZ expression as a prognostic indicator in colorectal cancer.
    Yuen HF; McCrudden CM; Huang YH; Tham JM; Zhang X; Zeng Q; Zhang SD; Hong W
    PLoS One; 2013; 8(1):e54211. PubMed ID: 23372686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.